Novartis Ag

University of Pennsylvania

Millennium Pharmaceuticals Limited

Abbott Laboratories Corporation

The General Hospital Corporation

Novartis Pharma Gmbh

Matthew J LaMarche

Jorge Garcia Fortanet

Zhuoliang Chen

Lawrence Blas Perez

Rajesh Karki

Martin Sendzik

Mitsunori Kato

Sarah Williams

Troy Douglas Smith

Christine Hiu-Tung Chen

Bakary-Barry Toure

Michael Dore

Amos B Smith, Iii

Thomas James Beauchamp

John William Giraldes

Bing Yu

Travis Matthew Stams

Lewis Whitehead

Simon Bushell

Denise Grunenfelder

Michael A Patane

Tricia J Vos

Michael David Shultz

Fan Yang

Alexandra E Gould

Roger A Fujimoto

Paul D Greenspan

Dyuti Majumdar

Philipp Krastel

Jennifer A Leeds

Hirokazu Arimoto

Patrick James Sarver

Emily Frances Calderwood

Pascal Furet

Gang Liu

Andrew J Souers

Philip R Kym

Robin Alec Fairhurst

Robert Mah

Michael D Kaufman

Kaoru Kobayashi

Anil Vasudevan

Bo Han

David R Jones

Rajesh R Iyengar

Martin P Maguire

Yuping Qiu

Catherine Leblanc

Paul Vincent Rucker

Can Wang

Su-Jen Lai

Mathew M Mulhern

Christopher Blackburn

Courtney A Cullis

Lv Liao

Dariusz Wodka

Jing Xiong

Nicole Buschmann

Mark Gabriel Palermo

Yuan Tian

Dale Porter

Fang Li

Markus Wartmann

Diana Graus Porta

Xianglin Zhao

Ju Gao

Jeffrey T Bagdanoff

John K Lynch

Thomas Knoepfel

Jennifer C Freeman

Huaixiang Hao

James A Brown

Jeffrey Engelman

Hans-Ulrich Naegeli

Ruth S Adams

Mary Katherin Verzal

Hui-Qin Wang

Robyn Scott Rowland

Jennifer L Che

Leila Dardaei Alghalandis

Victoriano Tamez, Jr

Andriana Jouk

Nafeeza Hafeez

Jennifer Leeds

The present invention relates to compounds of formula I:

N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2

A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

Compounds and compositions for inhibiting the activity of SHP2

The present invention relates to compounds of formula I:  in which m, Y, Y, Y, R, R, R, R, R, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2

The present invention relates to compounds of formula I: 

The present invention relates to compounds of formula I: in which p, q, Y, Y, R, R, R, R, R, R, R, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

The present invention relates to compounds of formula I: in which Y, Y, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2. 

1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2

1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2

A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combinations

Growing community of inventors

Reading, MA, United States of America

Matthew J LaMarche